Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18653879 | 0.85 | P2RX7 (0.42) | LMNAALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL7799847 | 0.85 | LMNA (0.55) | LMNAALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL7797771 | 0.85 | KMT2A (0.48) | LMNAALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL7801603 | 0.82 | KMT2A (0.40) | LMNAALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL7791617 | 0.82 | KMT2A (0.51) | LMNAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7801191 | 0.82 | KMT2A (0.40) | LMNAALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL7797711 | 0.81 | LMNA (0.49) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL7797756 | 0.80 | P2RX7 (0.44) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL29781598 | 0.80 | CYP3A4 (0.48) | LMNAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5795611 | 0.80 | ALDH1A1 (0.47) | LMNAALDH1A1MAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381307-A1 | TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED SYMPTOMS | PRICE RICHARD LOUIS (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230381307-A1 | TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED SYMPTOMS | PRICE RICHARD LOUIS (US) | 2023-11-30 | — | — | US | disclosed |
| US-11744891-B2 | Treatment of autism spectrum disorder and associated symptoms | PRICE RICHARD LOUIS (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744891-B2 | Treatment of autism spectrum disorder and associated symptoms | PRICE RICHARD LOUIS (US) | 2023-09-05 | — | — | US | disclosed |
| US-20200268882-A1 | TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED SYMPTOMS | PRICE RICHARD LOUIS (US) | 2020-08-27 | — | — | US | disclosed |
| US-10688179-B2 | Treatment of autism spectrum disorder and associated symptoms | PRICE RICHARD LOUIS (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190351054-A1 | TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED SYMPTOMS | PRICE RICHARD LOUIS (US) | 2019-11-21 | — | — | US | disclosed |
| US-10251865-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| EP-3332782-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-2605771-B1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20030092766-A1 | Methods and compositions for modulating alpha adrenergic receptor activity | ALLERGAN SALES, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003035178-A1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035178-A1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| US-6545182-B2 | For pain therapy | ALLERGAN SALES, INC. | 2003-04-08 | — | — | US | disclosed |
| EP-1280524-A2 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | Allergan, Inc. (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-1280525-A2 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | Allergan, Inc. (US) | 2003-02-05 | — | — | EP | disclosed |
| US-20020058839-A1 | Methods and compositions for modulating alpha adrenergic receptor activity | ALLERGAN SALES, INC. | 2002-05-16 | — | — | US | disclosed |
| US-6313172-B1 | ADMINISTERING HYDROXYETHYLTHIOUREA DERIVATIVE FOR THERAPY OF PAIN IN MAMMAL | ALLERGAN SALES, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001078702-A2 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001078703-A2 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688179-B2 | Treatment of autism spectrum disorder and associated symptoms | ITPR1, ITPR2, ITPR3 | LMNA 3822/4885ALDH1A1 748/4885MAPT 1328/4885 |
| US-20190351054-A1 | TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED SYMPTOMS | ITPR1, ITPR2, ITPR3 | LMNA 3822/4885ALDH1A1 748/4885MAPT 1328/4885 |
| US-20020058839-A1 | Methods and compositions for modulating alpha adrenergic receptor activity | ADRB2, ADRA2A, ADRA2C | LMNA 2350/4885ALDH1A1 1420/4885MAPT 2924/4885 |
| US-20230381307-A1 | TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED SYMPTOMS | ITPR1, ITPR2, ITPR3 | LMNA 3822/4885ALDH1A1 748/4885MAPT 1328/4885 |
| US-20030092766-A1 | Methods and compositions for modulating alpha adrenergic receptor activity | ADRB2, ADRA2A, ADRB1 | LMNA 2370/4885ALDH1A1 1656/4885MAPT 2572/4885 |
| US-20200268882-A1 | TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED SYMPTOMS | ITPR1, ITPR2, ITPR3 | LMNA 3822/4885ALDH1A1 748/4885MAPT 1328/4885 |
| US-11744891-B2 | Treatment of autism spectrum disorder and associated symptoms | ITPR1, ITPR2, ITPR3 | LMNA 3822/4885ALDH1A1 748/4885MAPT 1328/4885 |
| US-10251865-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ADRA2B, ADRB2, ADRA2A | LMNA 2921/4885ALDH1A1 887/4885MAPT 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.